Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.80
-0.04 (-0.51%)
At close: Dec 5, 2025, 4:00 PM EST
7.65
-0.15 (-1.92%)
After-hours: Dec 5, 2025, 6:00 PM EST
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
112
Market Cap
341.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionKYTX News
- 22 days ago - Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential - Seeking Alpha
- 24 days ago - Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 26 days ago - Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - GlobeNewsWire
- 5 weeks ago - Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025 - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS - GlobeNewsWire